In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands

Nuclear Medicine and Biology

Volumn 30, Issue 2, 2003, Pages 141-149

  Su, Zi Fen ^a,b   He, Jiang ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

V 3 integrin proteins; HUVE cells; RGD peptide; Technetium 99m labeling

Indexed keywords

ACETIC ACID DERIVATIVE; ARGININE; ASPARTIC ACID; ETHYLENEDIAMINE N',N' DIACETIC ACID; GLUTAMINE; GLYCINE; OCTANOL; PEPTIDE; PROTEIN; SERUM ALBUMIN; TECHNETIUM 99M; TRICINE; UNCLASSIFIED DRUG; WATER;

ARTICLE; BINDING AFFINITY; CATTLE; CELL CULTURE; CELL LYSATE; CONJUGATE; CONTROLLED STUDY; CYTOLYSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; PARTITION COEFFICIENT; PROTEIN BINDING; UMBILICAL VEIN;

BLOOD PROTEINS; CELLS, CULTURED; EDETIC ACID; ENDOTHELIUM, VASCULAR; GLYCINE; HUMANS; HYDRAZINES; INTEGRINS; LIGANDS; METABOLIC CLEARANCE RATE; NICOTINIC ACIDS; OLIGOPEPTIDES; PROTEIN BINDING; RADIOPHARMACEUTICALS; TECHNETIUM; UMBILICAL VEINS;

EID: 0037291284     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00390-6     Document Type: Article

References (37)

1. Reijneveld J.C., Voest E.E., Taphoorn M.J. Angiogenesis in malignant primary and metastatic brain tumors. J. Neurol. 247:2000;597-608.
2. Gasparini G. Angiogenesis research up to 1996, A commentary on the state of art and suggestions for future studies. Eur. J. Cancer. 32A:1996;2379-2385.
3. Davidson B., Reich R., Berner A., Givant-Horwitz V., Goldberg I., Risberg B., Kristensen G.B., Trope C.G., Bryne M., Kopolovic J., Nesland J.M. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur. J. Cancer. 37:2001;2040-2049.
4. Duong L.T., Lakkakorpi P., Nakamura I., Rodan G.A. Integrins and signaling in osteoclast function. Matrix Biol. 19:2000;97-105.
5. Weerasinghe D., McHugh K.P., Ross F.P., Brown E.J., Gisler R.H., Imhof B.A. A role for the alphavbeta3 integrin in the transmigration of monocytes. J. Cell. Biol. 142:1998;595-607.
6. Petitclerc E., Stromblad S., von Schalscha T.L., Mitjans F., Piulats J., Montgomery A.M., Cheresh D.A., Brooks P.C. Integrin alpha v beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 59:1999;2724-2730.
7. Chen Y., Xu X., Hong S., Chen J., Liu N., Underhill C.B., Creswell K., Zhang L. RGD-Tachyplesin inhibits tumor growth. Cancer Res. 61:2001;2434-2438.
8. Szaniawska B., Trembacz H., Miloszewska J., Lipkowski A.W., Misicka A., Ostrowski J., Janik P. Peptide analog of fibronectin that inhibits cell migration and ERK 1/2 activity. Peptides. 22:2001;1949-1953.
9. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
10. Westlin W.F. Integrins as targets of angiogenesis inhibition. Cancer J. 7:(Suppl 3):2001;139-143.
11. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., Gasparini G. Tumor angiogenesis a new significant and independent prognostic indicator in early-stage breast carcinoma . J. Natl. Cancer. Inst. 84:1992;1875-1887.
12. Horton M.A. Arg-Gly-Asp (RGD) peptides and peptidomimetics as therapeutics relevance for renal diseases . Exp. Nephrol. 7:1997;178-184.
13. Sivolapenko G.B., Skarlos D., Pectasides D., Stathopoulou E., Milonakis A., Sirmalis G., Stuttle A., Courtenay-Luck N.S., Konstantinides K., Epenetos A.A. Imaging of metastatic melanoma utilizing a technetium-99m labelled RGD-containing synthetic peptide. Eur. J. Nucl. Med. 25:1998;1383-1389.
14. Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., Kessler H., Schwaiger M. Glycosylated RGD-containing peptides tracer for tumor targeting and angiogenesis imaging with improved biokinetics . J. Nucl. Med. 42:2001;326-336.
15. Barrett J.A., Damphousse D.J., Heminway S.J., Liu S., Edwards D.S., Looby R.J., Carroll T.R. Biological evaluation of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models effects of chelators on biological properties of [99mTc]chelator-peptide conjugates . Bioconjug. Chem. 7:1996;203-208.
16. 99mTc by the preformed chelate approach effects of chelators on properties of [99mTc]chelator-peptide conjugates . Bioconjug. Chem. 7:1996;196-202.
17. 99mTc. Bioconjug. Chem. 8:1997;155-160.
18. Abrams M.J., Juweid M., tenKate C.I., Schwartz D.A., Hauser M.M., Gaul F.E., Fuccello A.J., Rubin R.H., Strauss H.W., Fischman A.J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med. 31:1990;2022-2028.
19. Ono M., Arano Y., Mukai T., Fujioka Y., Ogawa K., Uehara T., Saga T., Konishi J., Saji H. (99m)Tc-HYNIC-derivatized ternary ligand complexes for (99m)Tc-labeled polypeptides with low in vivo protein binding. Nucl. Med. Biol. 28:2001;215-224.
20. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug. Chem. 12:2001;624-629.
21. 1-octreotide . Eur. J. Nucl. Med. 27:2000;1580.
22. 111In-octreotide . J. Nucl. Med. 41:2000;1114-1119.
23. 3 integrin for tumor imaging. Bioconjug. Chem. 13:2002;561-570.
24. Su Z.F., Zhang X., Ballinger J.R., Rauth A.M., Pollak A., Thornback J.R. Synthesis and evaluation of two technetium-99mTc labeled peptidic 2-nitroimidazoles for imaging hypoxia. Bioconjug. Chem. 10:1999;897-904.
25. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99:1999;2235-2268.
26. 99mTc]chelator-peptide conjugates . Bioconjug. Chem. 7:1996;196-202.
27. 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Bioconjug. Chem. 10:1999;431-438.
28. Decristoforo C., Mather S.J. Technetium-99m somatostatin analogues effect of labelling methods and peptide sequence . Eur. J. Nucl. Med. 26:1999;869-876.
29. 111In-DTPA-D-Phe1-octreotide . Eur. J. Nucl. Med. 27:2000;628-637.
30. Decristoforo C., Mather S.J. 99m-Technetium-labelled peptide-HYNIC conjugates effects of lipophilicity and stability on biodistribution . Nucl. Med. Biol. 26:1999;389-396.
31. Liu S., Edwards D.S., Looby R.J., Harris A.R., Poirier M.J., Barrett J.A., Heminway S.J., Carroll T.R. Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands. Bioconjug. Chem. 7:1996;63-71.
32. 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl. Med. Biol. 22:1995;25-30.
33. van Hagen P.M., Breeman W.A., Bernard H.F., Schaar M., Mooij C.M., Srinivasan A., Schmidt M.A., Krenning E.P., de Jong M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer. 90:2000;186-198.
34. Castel S., Pagan R., Mitjans F., Piulats J., Goodman S., Jonczyk A., Huber F., Vilaro S., Reina M. RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. Lab. Invest. 81:2001;1615-1626.
35. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., Stocklin G., Schwaiger M. Radiolabeled alpha(v)beta3 integrin antagonists a new class of tracers for tumor targeting . J. Nucl. Med. 40:1999;1061-1071.
36. Haubner R., Wester H.J., Weber W.A., Mang C., Ziegler S.I., Goodman S.L., Senekowitsch-Schmidtke R., Kessler H., Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:2001;1781-1785.
37. Assa-Munt N., Jia X., Laakkonen P., Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry. 40:2001;2373-2378.